TY  - JOUR
AU  - Spelman, Timothy
AU  - Herring, William L
AU  - Zhang, Yuanhui
AU  - Tempest, Michael
AU  - Pearson, Isobel
AU  - Freudensprung, Ulrich
AU  - Acosta, Carlos
AU  - Dort, Thibaut
AU  - Hyde, Robert
AU  - Havrdova, Eva
AU  - Horakova, Dana
AU  - Trojano, Maria
AU  - De Luca, Giovanna
AU  - Lugaresi, Alessandra
AU  - Izquierdo, Guillermo
AU  - Grammond, Pierre
AU  - Duquette, Pierre
AU  - Alroughani, Raed
AU  - Pucci, Eugenio
AU  - Granella, Franco
AU  - Lechner-Scott, Jeannette
AU  - Sola, Patrizia
AU  - Ferraro, Diana
AU  - Grand'Maison, Francois
AU  - Terzi, Murat
AU  - Rozsa, Csilla
AU  - Boz, Cavit
AU  - Hupperts, Raymond
AU  - Van Pesch, Vincent
AU  - Oreja-Guevara, Celia
AU  - van der Walt, Anneke
AU  - Jokubaitis, Vilija G
AU  - Kalincik, Tomas
AU  - Butzkueven, Helmut
AU  - MSBase Investigators
PY  - 2021
DO  - 10.1007/s40273-021-01106-6
UR  - http://hdl.handle.net/10668/21696
T2  - PharmacoEconomics
AB  - Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as "BRACETD") often switch to...
LA  - en
KW  - Cost-Benefit Analysis
KW  - Fingolimod Hydrochloride
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Multiple Sclerosis
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Natalizumab
TI  - Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
TY  - research article
VL  - 40
ER  -